Tricida Inc (TCDA):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Tricida Inc (TCDA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8305
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:34
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Tricida Inc (Tricida), formerly Trilypsa Inc is a clinical-stage pharmaceutical and drug discovery company. The company discovers and develops novel non-absorbed therapies for the treatment of renal, metabolic and cardiovascular diseases. Its lead drug candidate TRC101, is under clinical development to treat metabolic acidosis a common complication of chronic kidney disease (CKD). Tricida plans to initiate a Phase III study to evaluate the safety and efficacy of TRC101 as a potential treatment for chronic metabolic acidosis associated with CKD. The company’s portfolio of investors includes OrbiMed, Sibling Capital, Limulus Venture Partners, Longitude Capital and Vivo Capital. Tricida is headquartered in South San Francisco, California, the US.

Tricida Inc (TCDA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Tricida Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Tricida Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Tricida Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Tricida Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Tricida Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Tricida Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Tricida Raises USD25 Million in Debt Financing 10
Tricida Raises Additional USD57.5 Million in Series D Financing 11
Tricida Raises USD55 Million in Series C Financing Round 13
Tricida Raises USD30 Million in Series B Financing 15
Tricida Raises USD10 Million in Series A Financing 16
Tricida Raises US$4.5 Million In Venture Financing 17
Equity Offering 18
Tricida Raises USD255.6 Million in IPO of Shares 18
Tricida Inc – Key Competitors 19
Tricida Inc – Key Employees 20
Tricida Inc – Locations And Subsidiaries 21
Head Office 21
Recent Developments 22
Financial Announcements 22
Aug 08, 2018: Tricida announces second quarter 2018 financial results and provides update on key initiatives 22
Corporate Communications 24
Jun 04, 2018: Tricida Names Kathryn Falberg As Board Director 24
Jan 08, 2018: Tricida Announces Hiring of Jeroen van Beek, Ph.D., as Chief Commercial Officer and Senior Vice President 25
Apr 11, 2017: Tricida Announces Hiring of Geoffrey Parker as Chief Financial Officer and Senior Vice President 26
Feb 15, 2017: Tricida appoints chief technology officer and senior vice president 27
Product News 28
02/15/2017: Tricida Announces Hiring of Wilhelm Stahl as Chief Technology Officer and Senior Vice President 28
01/09/2017: Tricida Announces Positive Topline Phase 1/2 Clinical Trial Results for TRC101 in 135 Subjects with Chronic Kidney Disease and Metabolic Acidosis 29
Clinical Trials 30
Jun 05, 2018: Tricida Announces Positive Pivotal Phase 3 Clinical Trial Results for TRC101 in CKD Patients With Metabolic Acidosis 30
Nov 07, 2017: Tricida Announces Publication of TRC101 Phase 1/2 Study Results Demonstrating a Rapid and Significant Increase in Serum Bicarbonate in Chronic Kidney Disease Patients with Metabolic Acidosis 31
Nov 01, 2017: Tricida Announces Podium Presentation at ASN Kidney Week 2017 of TRC101 Phase 1/2 Study Results in Patients with Metabolic Acidosis Associated with Chronic Kidney Disease 32
Sep 28, 2017: Tricida Initiates Phase 3 Study of TRC101 for the Treatment of Metabolic Acidosis Associated with Chronic Kidney Disease 33
Appendix 34
Methodology 34
About GlobalData 34
Contact Us 34
Disclaimer 34

List of Tables
Tricida Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Tricida Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Tricida Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Tricida Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Tricida Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Tricida Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Tricida Raises USD25 Million in Debt Financing 10
Tricida Raises Additional USD57.5 Million in Series D Financing 11
Tricida Raises USD55 Million in Series C Financing Round 13
Tricida Raises USD30 Million in Series B Financing 15
Tricida Raises USD10 Million in Series A Financing 16
Tricida Raises US$4.5 Million In Venture Financing 17
Tricida Raises USD255.6 Million in IPO of Shares 18
Tricida Inc, Key Competitors 19
Tricida Inc, Key Employees 20

List of Figures
Tricida Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Tricida Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Tricida Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Tricida Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Tricida Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Tricida Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Tricida Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Tricida Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Tricida Inc (TCDA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Perrigo Company plc:企業の戦略・SWOT・財務分析
    Perrigo Company plc - Strategy, SWOT and Corporate Finance Report Summary Perrigo Company plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • TetraLogic Pharmaceuticals (TLOG)-製薬・医療分野:企業M&A・提携分析
    Summary TetraLogic Pharmaceuticals (TetraLogic) is a biopharmaceutical company that research and develops novel small molecule therapeutics in the areas of oncology and infectious diseases. The company’s clinical stage products include birinapant and SHAPE. Its birinapant is a small molecule therape …
  • Emerson Radio Corporation (MSN):企業の財務・戦略的SWOT分析
    Emerson Radio Corporation (MSN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Hansa Medical AB (HMED):製薬・医療:M&Aディール及び事業提携情報
    Summary Hansa Medical AB (Hansa Medical) is a biopharmaceutical company that focuses on the development of novel immunomodulatory enzymes for transplantation and acute autoimmune diseases. The company's lead project, IdeS is a proprietary antibody-degrading enzyme in late stage clinical development …
  • Vossloh AG:企業の戦略・SWOT・財務情報
    Vossloh AG - Strategy, SWOT and Corporate Finance Report Summary Vossloh AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • KPC Pharmaceuticals Inc (600422):製薬・医療:M&Aディール及び事業提携情報
    Summary KPC Pharmaceuticals Inc (KPC), formerly Kunming Pharmaceutical Corp, a subsidiary of Holley Group Co Ltd, is a manufacturer of botanical drugs and other pharmaceutical products. The company offers panax notoginseng, gastrodine, artemether and special botanical drugs. It also offers drugs suc …
  • Northrop Grumman Corp (NOC):企業の財務・戦略的SWOT分析
    Northrop Grumman Corp (NOC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Zenkyoren:企業の戦略・SWOT・財務情報
    Zenkyoren - Strategy, SWOT and Corporate Finance Report Summary Zenkyoren - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • KDDI Corporation:企業の戦略・SWOT・財務情報
    KDDI Corporation - Strategy, SWOT and Corporate Finance Report Summary KDDI Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • FirstString Research Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary FirstString Research Inc (FirstString) is a biopharmaceutical company that discovers and develops therapies for inflammation and injury based medical conditions. The company markets new therapeutic products that enable physicians to treat unmet medical need. It offers therapeutic approach, w …
  • NewOcean Energy Holdings Ltd (342):企業の財務・戦略的SWOT分析
    NewOcean Energy Holdings Ltd (342) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • ProAxsis Ltd:企業の製品パイプライン分析2018
    Summary ProAxsis Ltd (ProAxsis), formerly ProAx-Sis Ltd, a subsidiary of NetScientific UK Ltd, is a developer of novel, point of care tests for the monitoring of patients with chronic diseases. The company develops proteasetags based point of care tests to offer a visual readout of active proteases …
  • Jack Henry & Associates Inc (JKHY):企業の財務・戦略的SWOT分析
    Jack Henry & Associates Inc (JKHY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Banco Hipotecario SA (BHIP3):企業の財務・戦略的SWOT分析
    Banco Hipotecario SA (BHIP3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • China National Materials Co Ltd:企業の戦略・SWOT・財務情報
    China National Materials Co Ltd - Strategy, SWOT and Corporate Finance Report Summary China National Materials Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Sol-Gel Technologies Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Sol-Gel Technologies Ltd (Sol-Gel) is a developer and manufacturer of topical dermatological drug products. The company’s products include Cool Pearls anti acne kit which is a benzoyl peroxide-based acne regime at commercial stage; and SGT-VD-54 is a non-antibiotic topical drug for the treat …
  • Selective Insurance Group, Inc. (SIGI):企業の財務・戦略的SWOT分析
    Selective Insurance Group, Inc. (SIGI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Invenergy LLC:企業の戦略的SWOT分析
    Invenergy LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Nathan’s Famous, Inc. (NATH):企業の財務・戦略的SWOT分析
    Nathan's Famous, Inc. (NATH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Scioderm Inc-製薬・医療分野:企業M&A・提携分析
    Summary Scioderm Inc (Scioderm), a subsidiary of Amicus Therapeutics Inc is a clinical stage biopharmaceutical company that develops various therapies. The company develops novel therapies for conditions including orphan diseases. Its product include Zorblisa (SD-101), is developed for treating the …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆